Qualigen therapeutics, inc. reports financial results and corporate update for quarter ending june 30, 2023

Investigational new drug (ind) clearance transitions qualigen from preclinical to clinical-stage company company divests fastpack ® diagnostics business for approximately $5 mi llion in all cash transaction to support advancement of therapeutics pipeline carlsbad, calif., aug. 15, 2023 (globe newswire) -- qualigen therapeutics, inc. (nasdaq: qlgn), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for orphan drug designation, today announces financial results for the second quarter ending june 30, 2023, and provides a corporate update: highlights for  second quarter and to date 2023: therapeutics highlights: qn-302 received us fda clearance to initiate phase 1 clinical trial of qn-302 for treatment of advanced or metastatic solid tumors presented four posters at the american association for cancer research (aacr) annual meeting, in april 2023: “a comparison of the activity of the quadruplex-targeting experimental drugs qn-302 and cx-5461 (pidnarulex) in wild-type and gemcitabine-resistant pancreatic cancer cell lines” ahmed ahmed, tariq arshad, and stephen neidle (poster) “the potent quadruplex-binding compound qn-302 down-regulates the s100p gene in vitro and in vivo models of pancreatic cancer: a potential therapeutic target and biomarker for pdac” nicole williams, jenny worthington, ahmed ahmed, tariq arshad, and stephen neidle (poster) “the potent quadruplex-binding compound qn-302 shows anti-tumor activity as a monotherapy in an orthotopic in vivo model of pancreatic cancer” nicole williams, danielle santos, jenny worthington, ahmed ahmed, tariq arshad and stephen neidle (poster) “structure-based design rules for potent quadruplex-binding compounds based on the naphthalene diimide core” stephen neidle (poster) pan-ras presented data at the american society of clinical oncology (asco) annual meeting, in june 2023: “impact of novel pan-ras inhibitors on efficacy and resistance to amg-510 and mrtx-1133 in pancreatic cancer cell lines.
QLGN Ratings Summary
QLGN Quant Ranking